This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Luca Rosti, MD; Deborah Piva, RN; Dario Rosti, MD
Neonatal Intensive Care Unit Ospedale Regina Elena via Manfredo Fanti 6 Milano, Italy 20122

Arch Pediatr Adolesc Med. 1994;148(10):1103-1104.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Patent ductus arteriosus (PDA) is common in premature infants younger than 33 weeks' gestational age (GA), and its deleterious effects are increased by the presence of respiratory distress syndrome. A significant proportion of infants younger than 33 weeks' GA have PDA.¹² Indomethacin has been used for the treatment of hemodynamically significant ductus, causing severe side effects, but even recently, it has been considered the only pharmacological approach to PDA.³

In the early 1980s, Morgan et al⁴ reported a reduction in the incidence of intraventricular hemorrhages in preterm neonates treated with ethamsylate, an inhibitor of prostaglandin biosynthesis.^4-6 Recently, ethamsylate has been reported to favor the closure of the ductus in preterm neonates with respiratory distress syndrome treated with exogenous surfactant.⁷

In 1987, we started prophylaxis of cerebral hemorrhages with ethamsylate (50 mg/kg per day in four intramuscular injections for 4 days, from the first day of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?